Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study

Schizophrenia Bulletin
Paul KlauserMichael W L Chee

Abstract

There is cumulative evidence that young people in an "at-risk mental state" (ARMS) for psychosis show structural brain abnormalities in frontolimbic areas, comparable to, but less extensive than those reported in established schizophrenia. However, most available data come from ARMS samples from Australia, Europe, and North America while large studies from other populations are missing. We conducted a structural brain magnetic resonance imaging study from a relatively large sample of 69 ARMS individuals and 32 matched healthy controls (HC) recruited from Singapore as part of the Longitudinal Youth At-Risk Study (LYRIKS). We used 2 complementary approaches: a voxel-based morphometry and a surface-based morphometry analysis to extract regional gray and white matter volumes (GMV and WMV) and cortical thickness (CT). At the whole-brain level, we did not find any statistically significant difference between ARMS and HC groups concerning total GMV and WMV or regional GMV, WMV, and CT. The additional comparison of 2 regions of interest, hippocampal, and ventricular volumes, did not return any significant difference either. Several characteristics of the LYRIKS sample like Asian origins or the absence of current illicit drug use could ...Continue Reading

References

Dec 18, 2001·Human Brain Mapping·Thomas E Nichols, Andrew P Holmes
Nov 1, 2002·Schizophrenia Research·Lisa J PhillipsPatrick D McGorry
Dec 14, 2005·The Australian and New Zealand Journal of Psychiatry·Alison R YungJoe Buckby
Jan 18, 2006·Schizophrenia Research·Ragy R GirgisAntonio Y Hardan
Aug 30, 2006·Psychological Medicine·Paul FearonUNKNOWN AESOP Study Group
Nov 14, 2006·Biological Psychiatry·Stefan J BorgwardtPhilip K McGuire
Mar 3, 2007·The British Journal of Psychiatry : the Journal of Mental Science·Philip R SzeszkoRobert M Bilder
Apr 19, 2007·International Journal of Epidemiology·Michaeline BresnahanEzra Susser
Sep 1, 2007·NeuroImage·John Ashburner
Nov 27, 2007·Lancet·Paolo Fusar-PoliPhilip McGuire
Feb 28, 2008·Journal of Magnetic Resonance Imaging : JMRI·Clifford R JackMichael W Weiner
Mar 8, 2008·NeuroImage·Chloe HuttonRobert Turner
Apr 3, 2008·The American Journal of Psychiatry·Ian Ellison-WrightEd Bullmore
Apr 24, 2009·Schizophrenia Bulletin·Johanna KoskinenJouko Miettunen
May 8, 2009·Schizophrenia Research·Tim B ZiermansHerman van Engeland
Sep 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·Nikolaos KoutsoulerisEva M Meisenzahl
Dec 23, 2009·Schizophrenia Bulletin·Wi Hoon JungJun Soo Kwon
Dec 31, 2009·Journal of Psychiatry & Neuroscience : JPN·Henning WitthausGeorg Juckel
Mar 13, 2010·Schizophrenia Bulletin·Killian A WelchEve C Johnstone
Sep 25, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Monica RaisRené S Kahn
Oct 12, 2010·Schizophrenia Bulletin·Tim B ZiermansSarah Durston
Oct 19, 2010·Biological Psychiatry·Petra HabetsUNKNOWN Genetic Risk and Outcome of Psychosis (G.R.O.U.P)
Dec 21, 2010·Neuroscience and Biobehavioral Reviews·P Fusar-PoliE Sacchetti
Feb 9, 2011·Archives of General Psychiatry·Beng-Choon HoVincent Magnotta
Apr 6, 2011·Archives of General Psychiatry·John P A Ioannidis
May 4, 2011·Archives of General Psychiatry·Andrea MechelliPhilip McGuire

❮ Previous
Next ❯

Citations

Oct 25, 2016·Neuroscience and Biobehavioral Reviews·Anna WalterTobias Vogel
Jan 13, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·New Fei HoJuan Zhou
Jan 18, 2018·Psychological Medicine·Maria Carmela PadulaStephan Eliez
Oct 20, 2017·American Journal of Medical Genetics. Part a·Sunny X Tang, Raquel E Gur
Oct 30, 2018·The Australian and New Zealand Journal of Psychiatry·Yoo Bin KwakJun Soo Kwon
Mar 13, 2020·Schizophrenia Bulletin·Daiki SasabayashiMichio Suzuki
Jan 6, 2017·Schizophrenia Bulletin·Paolo Fusar-Poli
Jun 1, 2017·NPJ Schizophrenia·Tae Young Lee, Jun Soo Kwon
May 29, 2020·Schizophrenia Bulletin·Roman BuechlerKarsten Heekeren
Apr 8, 2020·Journal of Psychiatry and Brain Science·Kathryn E LewandowskiMartha E Shenton
Oct 14, 2016·The Australian and New Zealand Journal of Psychiatry·Cali F BartholomeuszChristos Pantelis
Feb 2, 2021·Frontiers in Psychiatry·Bernd HinneyStefan Borgwardt
Jun 16, 2018·Brain, Behavior, and Immunity·Sina HafiziRomina Mizrahi
Apr 9, 2021·Frontiers in Psychiatry·Daiki SasabayashiMichio Suzuki
May 1, 2021·Biological Psychiatry : Cognitive Neuroscience and Neuroimaging·Katrina AberizkElaine F Walker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Risk Prediction

Cardiovascular risk prediction models based on classical risk factors identified in epidemiological studies are useful in primary prevention of cardiovascular disease in individuals. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.